A proton pump plays a key role in cell respiration as a specical membrane protein. A proton pump includes (H+/K+ ATPase) the gastric hydrogen potassium ATPase which is the proton pump of the stomach. The gastric H+,K+-ATPase, which is responsible for gastric acid secretion, is a P2-type ATPase located in the apical membrane of parietal cells. The enzyme is an α/β heterodimer. The α subunit, which has cation-binding and ATP-binding sites, plays a crucial role in catalytic activity. The β subunit is responsible for functional expression.
-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
Proton Pump Inhibitors
Other Transmembrane Transporters Related Inhibitors
| Cat.No. | Product Name | Information | Product Use Citations | Product Validations |
|---|---|---|---|---|
| S1413 | Bafilomycin A1 (Baf-A1) | Bafilomycin A1 (Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM, and it is found to inhibit autophagy while inducing apoptosis. |
|
|
| S1389 | Omeprazole | Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome. |
|
|
| S4845 | Rabeprazole | Rabeprazole(LY307640) is an oral inhibitor of proton pump and blocks the production of acid by the stomach. |
|
|
| S1354 | Lansoprazole | Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. This compound prevents the stomach from producing gastric acid. |
|
|
| S3666 | Ilaprazole | Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM. |
|
|
| S2105 | Pantoprazole | Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid. |
|
|
| S4665 | Rabeprazole sodium | Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors. |
|
|
| S4099 | Dexlansoprazole | Dexlansoprazole (T 168390, TAK 390,(R)-Lansoprazole), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. This compound selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell. |
|
|
| S5658 | Omeprazole Sodium | Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. This compound is a metabolism-dependent inhibitor (MDI) of CYP2C19. |
|
|
| S4212 | Tenatoprazole | Tenatoprazole (TU-199,STU-Na) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. This compound labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of this chemical is bound to the H(+),K(+)-ATPase. |
|
|
Signaling Pathway Map
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.